Pfizer Inc. (NYSE: PFE): Performance Review And Growth Outlook

In the last trading session, 36.87 million Pfizer Inc. (NYSE:PFE) shares changed hands as the company’s beta touched 0.59. With the company’s per share price at $27.59 changed hands at $0.16 or 0.58% during last session, the market valuation stood at $155.79B. PFE’s last price was a discount, traded about -53.03% off its 52-week high of $42.22. The share price had its 52-week low at $25.61, which suggests the last value was 7.18% up since then. When we look at Pfizer Inc.’s average trading volume, we note the 10-day average is 37.88 million shares, with the 3-month average coming to 43.35 million.

Pfizer Inc. (NYSE:PFE) trade information

Instantly PFE was in green as seen at the end of in last trading. With action -0.14%, the performance over the past five days has been red. The jump to weekly highs of 28.03 added 0.58% to the stock’s daily price. The company’s shares are showing year-to-date downside of -4.17%, with the 5-day performance at -0.14% in the red. However, in the 30-day time frame, Pfizer Inc. (NYSE:PFE) is 1.51% up. Looking at the short shares, we see there were 66.12 million shares sold at short interest cover period of 1.53 days.

Pfizer Inc. (PFE) estimates and forecasts

Data shows that the Pfizer Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -16.34% over the past 6 months, a 20.11% in annual growth rate that is considerably higher than the industry average of 4.40%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Pfizer Inc. will fall -59.30%, while the growth in revenue is estimated to hit -37.30% for the next quarter. Year-over-year growth is forecast to reach 2.50% up from the last financial year.

Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of $13.14 billion. 13 analysts are of the opinion that Pfizer Inc.’s revenue for the quarter ending Jun 2024 will be $12.25 billion. The company’s revenue for the corresponding quarters a year ago was $16.59 billion and $12.73 billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -20.80%. The estimates for the next quarter sales put growth at -3.80%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -27.43%. The 2024 estimates are for Pfizer Inc. earnings to increase by 20.34%, but the outlook for the next 5-year period is at -1.20% per year.

PFE Dividends

Pfizer Inc. is expected to release its next quarterly earnings report on May 01. The 5.98% annual yield figure for the share gives it an annual dividend of 1.65. It is important to note, however, that the 5.98% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.

Pfizer Inc. (NYSE:PFE)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.05% of Pfizer Inc. shares while 69.96% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 70.00%. There are 69.96% institutions holding the Pfizer Inc. stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 9.00% of the shares, roughly 508.09 million PFE shares worth $18.64 billion.

Blackrock Inc. holds the second largest percentage of outstanding shares, with 7.88% or 445.15 million shares worth $16.33 billion as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. With 176.05 million shares estimated at $6.46 billion under it, the former controlled 3.12% of total outstanding shares. On the other hand, Vanguard 500 Index Fund held about 2.38% of the shares, roughly 134.41 million shares worth around $4.93 billion.